mefatinib (MET306) / Huadong Medicine - LARVOL DELTA

Huadong’s Mefatinib Approved by NMPA for EGFR‑Driven NSCLC (flcube.com) - "The approval designates Mefatinib as the first‑line therapy for adult patients with locally advanced or metastatic non‑small‑cell lung cancer (NSCLC) carrying the EGFR exon 21 (L858R) substitution mutation."

China approval • Non Small Cell Lung Cancer

Mefatinib as first-line treatment of EGFR sensitizing mutation-positive non-small-cell lung cancer: A phase III efficacy and biomarker study. (ASCO 2024) - "Mefatinib is a new frontline option for EGFRmutant NSCLC. Co-occurring disruptive mutations caused decreased therapeutic efficacy of gefitinib, but had minimal impact on the PFS and OS of mefatinib. Comparing to gefitinib, PFS and OS improvements of mefatinib were most pronounced in patients with EGFR L858R mutation, especially those with disruptive co-occurring mutations."

Biomarker • Clinical • P3 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • HER-2 • TP53

Whole-genome sequencing reveals genotypic resistance in phenotypically susceptible Mycobacterium tuberculosis clinical isolates. (PubMed, Int J Mycobacteriol) - "The TB-Profiler software was used to call Single Nucleotide Variants (SNV) associated with resistance to rifampicin (RIF), isoniazid (INH), ethambutol (EMB), pyrazinamide, fluoroquinolone (FLQ), streptomycin (STR), and aminoglycosides...The most frequent predictive SNV were; rpoB Ser450 Leu for RIF; katG Ser315Thr, inhA Ser94Ala, fabG1-15C >T (for INH); gyrA Asp94Gly for FLQ; embB Met306 Leu for EMB; rpsL Lys43Arg for STR; and tlyA Asn236 Lys for Capreomycin. Our study highlights the value of WGS-based sequence data for identifying resistance in MTB. It also shows how MTB strains may be misclassified simply on phenotypic drug susceptibility testing, and that correct genome interpretation is key for correct interpretation of resistance genotypes that can be used to guide clinical treatment."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations. (PubMed, Cancer Commun (Lond)) - No abstract available

Journal • Metastases • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Mefatinib as first-line treatment of patients with advanced non–small cell lung cancer harboring rare EGFR mutations. (ASCO 2022) - "Mefatinib has shown promising anti-tumor activity and a favorable safety profile in patients with advanced NSCLC harboring rare EGFR mutations."

Clinical • Dental Disorders • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Stomatitis • EGFR